The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study

Overview

Journal Turk J Ophthalmol

Specialty Ophthalmology

Date 2025 Jan 2

PMID 39743937

Authors

Kubra Ozdemir Yalcinsoy

Osman Ozen

Yasemin Ozdamar Erol

Pinar Cakar Ozda

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the clinical features of pediatric non-infectious uveitis (NIU) patients treated with adalimumab (ADA) and the efficacy of ADA in patients unresponsive to conventional immunosuppressive therapy.

Materials And Methods: The records of 91 NIU patients aged ≤16 years who received ADA therapy were evaluated retrospectively. The patients' demographic and clinical characteristics and treatment approaches were recorded. The efficacy of ADA in patients treated for at least 1 year after failure of conventional immunosuppressive treatment was evaluated by comparing the best corrected visual acuity (BCVA), severity of intraocular inflammation, uveitis flare-ups, topical and systemic corticosteroid (CS) use, and central macular thickness (CMT) values before and after ADA treatment.

Results: The study included 103 eyes of 53 patients, of whom 29 (54.7%) were female. The mean age at presentation was 8.2±3.4 (range: 3-16) years. The mean follow-up period was 41.6±28.2 (range: 18-120) months. Twenty-six patients (49.0%) had anterior uveitis, 22 (41.5%) had intermediate uveitis, and 5 (9.4%) had panuveitis. The mean duration of ADA treatment was 23.0±13.7 (range: 12-60) months. Uveitis flare-ups developed in only 13 patients (24.5%) while on ADA treatment. When pre- and post-treatment periods were compared, the mean number of uveitis flare-ups, intraocular inflammation severity, mean dose of topical and systemic CS, and mean CMT values were significantly lower in the post-treatment period (p<0.05). The mean BCVA was significantly improved after 6 and 12 months of ADA treatment compared to the pre-treatment visual acuity (p<0.05).

Conclusion: ADA effectively controlled intraocular inflammation, reducing the need for systemic and topical CS and improving visual outcomes in pediatric NIU.

References

Rosenberg K, Feuer W, Davis J . Ocular complications of pediatric uveitis. Ophthalmology. 2004; 111(12):2299-306. DOI: 10.1016/j.ophtha.2004.06.014. View

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

Markomichelakis N, Aissopou E, Chatzistefanou K . Pediatric Non-Infectious Uveitis: Long-Term Outcomes and Complications. Ocul Immunol Inflamm. 2023; 31(10):2001-2008. DOI: 10.1080/09273948.2022.2162422. View

Mochizuki M, Smith J, Takase H, Kaburaki T, Acharya N, Rao N . Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019; 103(10):1418-1422. DOI: 10.1136/bjophthalmol-2018-313356. View

Ozdemir H, Cakar Ozdal P . Clinical characteristics and treatment of pars planitis: an adalimumab experience. Graefes Arch Clin Exp Ophthalmol. 2021; 260(2):561-569. DOI: 10.1007/s00417-021-05398-4. View

Tugal-Tutkun I . An Overview of Pediatric Uveitis. Turk Arch Pediatr. 2023; 58(4):363-370. PMC: 10441137. DOI: 10.5152/TurkArchPediatr.2023.23086. View

Thorne J, Woreta F, Dunn J, Jabs D . Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010; 117(7):1436-41. PMC: 2900491. DOI: 10.1016/j.ophtha.2009.12.003. View

Lam D, Fan D, Ng J, Yu C, Wong C, Cheung A . Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Exp Ophthalmol. 2005; 33(3):252-8. DOI: 10.1111/j.1442-9071.2005.01022.x. View

Bazewicz M, Heissigerova J, Pavesio C, Willermain F, Skrzypecki J . Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis. J Ophthalmic Inflamm Infect. 2023; 13(1):41. PMC: 10507006. DOI: 10.1186/s12348-023-00364-z. View

10.

Roberts J, Nigrovic P, Lo M, Chang M . Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children. J Clin Rheumatol. 2021; 28(1):e301-e304. PMC: 8443693. DOI: 10.1097/RHU.0000000000001707. View

11.

Sonmez H, Evereklioglu C, Gulmez Sevim D . Prompt and Sustained Suppression of Intraocular Inflammation with Adalimumab in Pediatric Patients with Non-Infectious Uveitis Resistant to Traditional Managements: A 6-Month Follow-Up Research. Ocul Immunol Inflamm. 2022; 31(10):1992-1996. DOI: 10.1080/09273948.2022.2139274. View

12.

Quartier P, Baptiste A, Despert V, Allain-Launay E, Kone-Paut I, Belot A . ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2017; 77(7):1003-1011. DOI: 10.1136/annrheumdis-2017-212089. View

13.

Tao T, Yang S, He D, Peng X, Wang Z, Jiang Q . The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study. Ophthalmol Ther. 2024; 13(5):1239-1253. PMC: 11039589. DOI: 10.1007/s40123-024-00884-4. View

14.

Ozdal P, Sen E, Yazici A, Ozturk F . Patterns of childhood-onset uveitis in a referral center in Turkey. J Ophthalmic Inflamm Infect. 2011; 2(1):13-9. PMC: 3303000. DOI: 10.1007/s12348-011-0044-8. View

15.

Norcia L, Kiappe O, Jorge E . Biological Therapy in Noninfectious Pediatric Uveitis: A Systematic Review. Clin Ophthalmol. 2021; 15:3765-3776. PMC: 8434856. DOI: 10.2147/OPTH.S322445. View

16.

Nussenblatt R, Palestine A, Chan C, Roberge F . Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985; 92(4):467-71. DOI: 10.1016/s0161-6420(85)34001-0. View

17.

Yuan P, Hu Y, Chen X, Chen G, Pan Y, Lao H . Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open-Label, Prospective, Pilot Study. Ocul Immunol Inflamm. 2024; :1-8. DOI: 10.1080/09273948.2024.2343084. View

18.

Correll C, Bullock D, Cafferty R, Vehe R . Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2017; 37(2):549-553. DOI: 10.1007/s10067-017-3890-4. View

19.

Mehta P, Alexander J, Sen H . Pediatric uveitis: new and future treatments. Curr Opin Ophthalmol. 2013; 24(5):453-62. PMC: 5569244. DOI: 10.1097/ICU.0b013e3283641ede. View

20.

Ekici Tekin Z, Yener G, Akbulut S, Cetin E, Yuksel S . Follow-up Findings of Non-infectious Pediatric Uveitis Patients. Turk J Ophthalmol. 2021; 51(6):351-357. PMC: 8715655. DOI: 10.4274/tjo.galenos.2021.38585. View